RecruitingNot ApplicableNCT07646197

Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD


Sponsor

Henry Ford Health System

Enrollment

125 participants

Start Date

Jun 9, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver. * Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm. * Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention * Daily log to be completed for tracking peanut consumption * 2-day Dietary recall at baseline, during Week 6 and Week 12 * Poat intervention Fibro scans for participants with baseline scans available


Eligibility

Min Age: 30 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Peanut consumption for people with fatty liver and masld. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPeanut consumption

MASLD patients will consume 50 gm of peanut daily for 12 weeks


Locations(1)

Henry Ford Health System

Detroit, Michigan, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07646197


Related Trials